Pluristem Receives FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant
January 12, 2016 at 04:18 AM EST
Pluristem Therapeutics Inc. (Nasdaq: PSTI) announced today that the U.S. Food and Drug Administration (FDA) cleared the Company's ...
